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Introduction: Earlier, we showed that in cancer cells, AMP-activated kinase (AMPK) participates in a signal
transduction pathway involving ATM-AMPK-p53/p21cip1 which is activated by ionizing radiation (IR) to mediate
G2-M arrest and enhanced cytotoxicity. We also observed that AMPK modulates ATM expression and activity and
the IR response of the Akt-mTOR pathway. Since the ATM, AMPK and Akt pathways are key targets of novel
radio-sensitizing therapeutics, we examined the chronic modultion of expression and activity of those pathways by
IR alone in xenograft models of lung cancer.
Methods: Immuno-compromised mice were grafted with human lung A549 and H1299 cells, were treated with
a single fraction of 0 or 10 Gy, and left to grow for 8 weeks. Extracted tumors were subjected to lysis and
immunoblotting or fixation and immunohistochemical analysis.
Results: IR inhibited significantly xenograft growth and was associated with increased expression of Ataxia
Telengiectasia Mutated (ATM) and enhanced phosphorylation of two ATM targets, H2Ax and checkpoint kinase
Chk2. Irradiated tumours showed increased total AMPK levels and phosphorylation of AMPK and its substrate
Acetyl-CoA Carboxylase (ACC). IR led to enhanced expression and phosphorylation of p53 and cyclin dependent
kinase inhibitors p21cip1 and p27kip1. However, irradiated tumours had reduced phosphorylation of Akt, mTOR and
it‘s target translation initiation inhibitor 4EBP1. Irradiated xenografts showed reduced microvessel density, reduced
expression of CD31 but increased expression of hypoxia-induced factor 1A (HIF1a) compared to controls.
Conclusion: IR inhibits epithelial cancer tumour growth and results in sustained expression and activation of
ATM-Chk2, and AMPK-p53/p21cip1/p27kip1 but partial inhibition of the Akt-mTOR signaling pathways. Future studies
should examine causality between those events and explore whether further modulation of the AMPK and Akt-
mTOR pathways by novel therapeutics can sensitize lung tumours to radiation.
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In tumor cells ionizing radiation (IR) activates within
minutes the protein kinase B (Akt) and mammalian
Target of Rapamycin (mTOR) pathway leading to radio-
resistance and tumor survival [1]. Akt and mTOR are
established effectors of tyrosine kinase receptors such as* Correspondence: theos.tsakiridis@jcc.hhsc.ca
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reproduction in any medium, provided the orEGF receptor (EGFR), which modulates the activity
of these molecules through a pathway involving phos-
phatidylinositol 3-kinase (PI3k) and phosphoinositide-
dependent kinase 1 (PDK1) [2]. Akt kinase acts as a
main activator of mTOR, up regulation of which is
known to occur by at least two different steps: i) phos-
phorylation and inhibition of Tuberous Sclerosis Com-
plex 2 (TSC2), that inactivates GTPase activity of the
GTP-binding protein Rheb leading to mTOR activation
[3] and ii) stimulation of mTOR activity through phos-
phorylation of PRAS40, a member of mTORC1, one ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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includes mLST8/Gbl and the scaffold protein Raptor [4].
To date, extensive published work demonstrated the im-
pact of mTOR on cell growth, cancer cell proliferation
and resistance to cytotoxic agents [5] mTORC1 regu-
lates multiple growth and gene expression pathways
and specifically stimulates mRNA translation through
phosphorylation and activation of the ribosomal p70S6-
kinase (p70s6k) and phosphorylation-induced inhibition
of the translation initiation inhibitor eIF4E binding pro-
tein 1 (4EBP1) [5].
Recently, we showed that IR activates acutely the en-
ergy sensor and tumor suppressor AMP-activated kinase
(AMPK) pathway, an evolutionally-preserved kinase that
mediates a metabolic checkpoint on cell cycle when cells
are under stress [6]. AMPK is an effector of Liver Kinase
B 1 (LKB1), a tumour suppressor mutated in Peutz-
Jeghers syndrome, which is associated with benign and
malignant epithelial tumors [7]. AMPK is a heterotri-
meric enzyme of α, β and γ subunits that senses low
energy levels through AMP binding on the γ subunit
and is regulated by phosphorylation of the α subunit on
Thr172 [8]. AMPK inhibits anabolic processes and pro-
tein synthesis by inhibition of mTORC1 through differ-
ent mechanisms including, i) Ser1387 phosphorylation
and activation of TSC2, leading to enhanced Rheb
GTPase activity and mTOR inhibition and ii) by Raptor
phosphorylation [9]. In addition, AMPK mediates cell
cycle checkpoints through induction of p53 and the
cyclin-dependent kinase inhibitors (CDKI) p21cip1 and
p27kip1 leading to cell cycle arrest [6,10].
We have suggested that, apart from its metabolic
action, AMPK is activated by IR and may be a mediator
of DNA damage signals. We implicated AMPK in the
mediation of IR-induced signal transduction through
an Ataxia Telengiectasia mutated (ATM)-AMPK-p53-
p21cip1 pathway to facilitate G2/M cell cycle arrest and
mediate radiosensitization [6]. However, the effects of IR
on AMPK subunit expression and chronic regulation of
its activity have not been examined in human tumours.
Furthermore, the levels of expression and activation of
the Akt and mTOR pathways have not been analyzed
extensively in irradiated tumours long after treatment.
Here, we analyzed in two different human non-small cell
lung cancer xenograft models the effects of a single frac-
tion of IR on the long term expression and activation of




Balb/c immune-compromised nude mice were obtained
from Charles River (Mississauga, Ontario, Canada). At
five weeks of age, animals were injected into the rightflank with 1x106 A549 or H1299 human lung adenocar-
cinoma cells. Once tumours reached 100 mm3, animals
were equally divided into non-irradiated (control: 0 Gy)
or ionizing radiation (IR: 10 Gy) treated groups (n = 6
per group). Tumour volume was measured every 3 days
with calliper according to the formula: V=Lenght*Width*-
Height*0.5236. Eight weeks after treatment, tumours were
extracted and snap-frozen in liquid nitrogen for lysis, total
protein extraction and immunoblotting or were formalin
fixed and paraffin embedded for immunohistochemistry
(IHC) analysis. Tumour lysates were prepared from frozen
tumours that were sectioned, mechanically homogenized
in RIPA (Radio-Immunoprecipitation Assay) buffer and
manually processed with Dounce homogenizer for total
protein extraction.
Animal irradiation
After appropriate dosimetry, conformal IR treatment
(10 Gy) was delivered to xenografts with a clinical radio-
therapy unit while animals were anaesthetized and housed in
a Plexiglas tube equipped with High-Efficiency-Particulate-
Air-(HEPA) filters.
Immunoblotting
Immunoblotting was performed as described previously
[6]. Antibodies for total AMPKα, P-AMPKα (Thr172),
P-ACC(Ser79), ATM, γH2AX (Ser139), P-Chk2 (Thr68),
P-p53 (Ser15), p27kip, p21waf/cip, mTOR, P-mTOR
(Ser2448), Akt, P-Akt (S473), P-Akt (Thr308), P-4EBP1
(Thr37/46), CD31 and HIF1α were purchased from Cell
Signalling Technology (Mississauga, Ontario, Canada).
Antibodies against p53 and β-actin were supplied by
Millipore (Etobicoke, Ontario, Canada).
Immunohistochemistry
Four μm thick tumour sections were mounted onto
slides, deparaffinised, followed by antigen retrieval,
blocking with goat serum and incubated with primary
antibody against P-AMPKα (Thr172) (1:200), anti-CD31
(1/500) dilution overnight and processed as described
earlier [11].
Statistical analysis
Quantitation and normalization of immunoblotting
results was pursued for all xenograft lysates and anti-
bodies (12 per tumour type and 6 per condition, Control
vs irradiated). All density values of each immublotting
band were first normalized against a value that for each
blot was defined by the average density of the 6 control
(untreated) lysates in each tumor type. Mean and SE
values were determined after this normalization.
Paired t-test was performed to analyze the results from
immunoblotting experiments using SPSS software (SPSS,
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istical significance was determined at p< 0.05 (*).
Results
Effects of IR on lung cancer xenograft growth
Within 15 days after IR treatment, xenografts began to
show differences in growth kinetics that became statisti-
cally significant by day 25 (Figure 1). At the end of the
8 week period irradiated tumours were on average
67 ± 3.4 % (A549) and 70 ± 4.2 % (H1299) smaller than
their control (non-irradiated) counterparts.
Effects of IR on the ATM expression and activity
We examined the effects of IR on the total protein levels
and the activity of ATM. Eight weeks after IR treatment
A549 xenografts exhibited significantly increased levels
of total ATM protein (Figure 2a). To evaluate the activity
of ATM we assessed the phosphorylation levels of two
established targets of this kinase, histone H2AX and the
checkpoint kinase Chk2. In both A549 and H1299 xeno-
grafts we detected increased levels of phosphorylated
H2AX (γH2AX) in the irradiated tumours compared to
untreated control tumours that were significantly higher
in H1299 xenografts (Figure 2A-B). Similarly, irradiated
A549 and H1299 xenografts showed increased Chk2
phosphorylation (P-Chk2). That was statistically signifi-
cant in H1299 but not in A549 xenografts when all
tumours were analyzed (Figure 2).
Chronic regulation of expression and activity of AMPK
by IR
In recent studies with tissue cultures of A549 cells, we
observed that within 24-48 h IR stimulates expression






























Figure 1 Ionizing radiation (IR) suppresses A549 and H1299 lung can
male mice were grafted with A549 or H1299 cells and left to 100 mm³ and
Tumour volume was monitored every 3 days for a period of 8 weeks. Repr
compared with control tumour volume.[25]. For that we examined here whether those effects
of IR could be sustained in xenografts long after IR de-
livery. The levels of total AMPKα, P-AMPK and P-
Acetyl CoA Carboxylase (P-ACC), a substrate of AMPK
indicating AMPK kinase activity, were examined in con-
trol and irradiated A549 and H1299 tumours. Basal
levels of total AMPK α subunit increased in irradiated
xenografts along with activation of the enzyme marked
by phosphorylation on Thr172 residue (Figure 3A-C).
P-ACC levels were also significantly higher in tumours
collected from irradiated xenografts compared to con-
trol (Figure 3 A and B). Figure 3B shows the quantita-
tion results of immunoblotting experiments of 6
xenografts per group. To examine whether increased
levels of P-AMPK (Thr172) signals are indeed attribu-
ted to cancer cells, rather than to the surrounding
tumor microenvironment, we have performed immuno-
histochemistry analysis of xenografts using anti-P-
AMPK (Thr172) antibody (Figure 3C). In those experi-
ments we also observed significant increases in P-
AMPK in irradiated tumour cells compared to controls
that distributed both cytoplasm and nuclei of tumor
cells of A549 origin but mainly in cytoplasm of H1299
tumour cells.
Regulation of steady state levels of p53 and CDKIs by IR
To examine the effects of IR treatment on cell cycle check-
point regulators, lysates of control and IR-treated xenografts
were probed with anti-p53, P-p53 (Ser15), p27kip1 and p21cip1
antibodies. Figure 4A-C shows that a single fraction of IR
induces a sustained significant increase, of p27kip1 and p21cip1
levels in irradiated A549 and H1299 tumours. We analyzed
total and phosphorylated (P-) p53 levels specifically in A549H1299 































cer tumour growth in vivo. Twelve four week old male balb/c nude
were treated with a single fraction of 0 Gy (Control) or 10 Gy R.













Figure 2 Ionizing radiation (IR) induces sustained stimulation of the DNA damage response pathway. (A) Tumour tissue extracted from
Control and IR–treated animals were subjected to immunoblotting analysis using ATM, P-Chk2 and γH2AX (Ser139) antibodies. Anti-actin was
used as a loading control. Representative immunoblots from 6 independent experiments are shown. (B) Immunoblot densitometric values are
shown as percent change in protein expression relative to the control group (*p< 0.05).
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ingly, we detected highly significant increase in total and phos-
phorylated (Ser15: 5.5-fold increase) p53 levels in irradiated
tumours.
IR mediates a long term suppression of the Akt-mTOR
pathway
We did not detect significant differences in the total
Akt levels between control and irradiated tumours(Figure 5). However, we observed that IR caused a sus-
tained reduction in the levels of P-AktS473 in both A549
and H1299 xenografts that reached significance in A549
but not in H1299 tumours. A trend for reduced P-
AktT308 levels was also detected in irradiated tumours
of both types but that was not statistically significant
in either of them (30.0 + 6.4% and 55.0 + 10.9% vs
15.0 ± 4.3% and 42.0 ± 2.3% decrease for T308 and

















Figure 3 Ionizing Radiation (IR) upregulates AMPK expression and activity in A549 and H1299 lung xenografts in-vivo. (A) Control and
IR-treated tumours were subjected to immunoblotting analysis using AMPKα, P-AMPK (Thr172), and P-ACC antibodies. Anti-actin was used as a
loading control. A representative immunoblot of 6 independent experiments is shown. (B) Immunoblot densitometric values are shown as
percent change in protein expression relative to the control group p (*p< 0.05; **p< 0.001). (C) A549 and H1299 tumours were fixed and
immunohistochemistry analysis was performed using a specific P-AMPK antibody.
Storozhuk et al. Radiation Oncology 2012, 7:71 Page 5 of 11
http://www.ro-journal.com/content/7/1/71(Figure 5B, D). Consistently, both IR-treated tumour
types showed reduced P-mTOR (Ser2448) levels without
a significant change in total-mTOR levels. Irradiated
xenografts of the two lung cancer types showed reduced
levels of phosphorylation of 4EBP1 (P-4EBP1) indicating
reduced mTOR activity (reduction by 81.0 ± 4.75% and
47.0 ± 3.20% in A549 and H1299 xenografts, respectively)
(Figure 5A-B).
Levels of microvasculature and hypoxia markers in
irradiated xenografts
Since hypoxia is known to modulate tumour IR
responses and ATM activity, we examined the levels of
the endothelial protein CD31, as a marker of microvas-
culature density, and those of HIF1α, as marker of hyp-
oxia, in control and irradiated xenografts from both lung
cancer A549 and H1299 xenografts. Figure 6A and B
illustrates representative immunoblots and quantitation
of results from all xenografts. Both types of irradiatedxenografts showed significantly reduced levels CD31 and
increased levels of HIF1α in comparison to untreated
tumours (Figure 6A, B). We performed immunohisto-
chemistry experiments with the antibody against CD31
to verify whether indeed the reduced expression of CD31
levels corresponded to a reduced density of microvessels
in irradiated tumours. All six tumours per group were
analyzed. Figure 6C shows representative images from
these experiments illustrating a significantly reduced
density of microvessels in the irradiated A549 tumours.
Discussion
The Akt-mTOR pathway is an established mediator of
radio-resistance and novel biological inhibitors of the
two kinases are shown to sensitize tumour cells to IR
[12,13]. On the other hand, AMPK is an emerging
metabolic and genomic stress sensor that is also a
promising target of novel cancer therapeutics such as
the anti-diabetic agent metformin. Metformin inhibits






















Figure 4 Ionizing radiation (IR) activates cell-cycle regulatory proteins in lung cancer tumour xenographts. (A) Tumour tissue
extracted from Control and IR–treated animals were subjected to immunoblotting analysis using p53, P-p53 (Ser15), p27kip, and p21waf/cip
antibodies. Anti-actin immunoblotting was used as a loading control. A representative immunoblot from 6 independent experiments is shown.
(B) Immunoblot densitometric values are shown as percent change in protein expression relative to the control group (*p< 0.05; **p< 0.001).
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radio-sensitizing properties in lung cancer in-vitro [6]
These notions suggest a need to understand in depth the
effects of IR on the expression and activity of the Akt-mTOR and AMPK signaling pathways in tumours in order
to understand better tumour radiation biology and as-
sist in a rational development of new effective radio-















Figure 5 Ionizing Radiation (IR) inhibits Akt-mTOR pro-survival pathway in A549 and H1299 lung carcinoma xenografts. (A) Lysates
from Control and IR treated tumours were subjected to immunoblot analysis using Akt, P-Akt (S473), P-Akt (Thr308), mTOR, P-mTOR (Ser2448)
and P-4EBP1 antibodies. A representative immunoblot from 6 independent experiments is shown. (B) The immunoblot densitometric values are
shown as percent change in protein expression relative to the control group (*p< 0.05; **p< 0.001).
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of expression and activity of AMPK and Akt pathway
members. Tumours were extracted and analyzed 8 weeks
after radiation as this is a typical protocol in pre-clin-
ical radio-sensitizer studies. Two different NSCLC
tumour models with distinct molecular defects (A549:K-Ras (G12S) oncogenic mutant and truncated LKB1-null
but wild-type p53 vs H1299: p53-null, wild-type K-Ras and
LKB1) were used to examine whether detected chronic re-
sponse of the AMPK-p53/CDKIs and Akt-mTOR pathways




















Figure 6 Ionizing Radiation (IR) downregulates CD31 and enhances HIF1α levels in human lung cancer tumours. (A) Lysates from
control and irradiated tumours were subjected to immunoblot analysis using CD31 and HIF1α antibodies. A representative immunoblot from
6 independent experiments is shown. (B) Average normalized densitometric values are shown as percent change in protein expression relative
to the control group (*p< 0.05; **p< 0.001). (C) A549 tumours were fixed and immunohistochemistry analysis was performed using a specific
anti-CD31 antibody.
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fraction of IR (10 Gy) caused an expected significant
inhibition of tumour growth kinetics (Figure 1). Since
our earlier studies suggested that AMPK is an effector
of ATM [6] and other work pointed to direct modula-
tion of Akt activity by ATM [14] we explored the effect
of IR on ATM expression and activity. Interestingly,
we observed increased total ATM levels and increased
phosphorylation of two ATM targets, histone H2AX
and Chk2 (Figure 2). Both events are well described
acute effects of IR. Enhanced levels of H2AX have
also been described in human tumours 24 h after a
clinical dose of radiotherapy of 2 Gy [15]. However,
our results suggest a sustained increased activity of
ATM-γH2AX DNA damage response pathways long
after exposure to IR treatment which can be respon-
sible for the increased activity of the AMPK pathway
discussed below.The detection of a sustained enhancement of AMPKα
protein levels and activity in tumours long after IR is a
novel finding in this study (Figure 3). Irradiated tumours
had significantly higher levels of total and phosphory-
lated AMPK as well as P-ACC suggesting maintained
enhanced expression and activity of the enzyme. Since
we and others have shown that AMPK is a transducer
of ATM signals [6,16] sustained activation of AMPK
would be an expected finding in the presence of ATM
activation. However, our results also showed increased
AMPKα protein levels, suggesting that IR drives AMPKα
gene expression. In recent studies with lung (A549) and
breast cancer cells (MCF7 and MB-231), we observed
that within 24 and 48 hour IR enhances not only the
activity of AMPK but also the levels of mRNA and pro-
tein of AMPKα, β and γ subunits [17] indicating that IR
regulates AMPK gene expression at both the transcrip-
tional and the translational level. Those results suggested
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within 24 – 48 h that is maintained long after the geno-
toxic insult is delivered. The specific mechanism and
transcription factors involved in these events remain
to be elucidated but studies suggest involvement of the
p53-dependent stress-responsive genes Sestrin 1 and 2
[18]. The regulation of AMPK gene expression and
activity in response to IR is likely a universal pheno-
menon in epithelial tumour cells. Similar to observations
in lung cancer xenografts, we have observed sustained
enhancement of total and phosphorylated AMPK α sub-
unit levels in xenografts of PC3 prostate cancer cells
also, a cell line that lacks expression p53 (see Additional
file 1: Figure S1). Therefore, overall our results suggest
that IR triggers acute and chronic expression of AMPK
genes as well as activation of this enzyme that is likely
universal in epithelial cancer cells and is independent of
p53. Currently, we analyze the exact role of sestrin genes
in these processes.
Importantly, we observed that irradiated tumours
maintain significantly increased levels of total and phos-
phorylated p53 and of CDK inhibitors p21cip1 and
p27kip1 (Figure 4). We also detected in irradiated
tumours highly increased level of p53-Ser15 phosphoryl-
ation a post-translational modification believed to con-
tribute to a greater stability of this protein [14]. These
results support the notion that IR activates the p53/
CDKI signaling pathways in tumours in a sustained fash-
ion probably through increased expression, phosphoryl-
ation and stabilization of p53 and increased levels of
CDKIs p27kip1 and p21cip1 (Figure 4). The p53-p21cip1
pathway is an established target for ATM [19] and
AMPK [6,8] both of which were suggested to phosphor-
ylate p53. Earlier, we showed that induction of p53 and
p21cip1 in response to IR is dependent on AMPK and
that AMPK activity is required for the mediation of IR-
induced G2-M checkpoint and IR cytotoxicity [6].
AMPK may indeed mediate the inhibitory effects of IR
on xenograft growth through regulation of p53 and
CDKIs. Similar to our earlier observation on the acute
response of p21cip1 to IR in A549 and H1299 cell cul-
tures [6], the induction of this CDKI in irradiated xeno-
grafts does not appear to depend on p53 as it was
observed in p53-null H1299 xenografts also (Figure 4 A).
IR is known to mediate a rapid activation of Akt [20]
and recent studies showed that ATM can function as an
activating Akt kinase that phosphorylates rapidly Akt-
S473 [21]. Despite that, and the detection of increased
ATM activity in radiated xenografts (Figure 2), we
observed significantly reduced levels of Akt-S473 phos-
phorylation in both types of lung cancer xenografts and
a trend for reduced AktT308 phosphorylation. Consist-
ently, mTOR phosphorylation was partially reduced and
so was the activity of this key enzyme indicated by lower4EBP1 phosphorylation that was more significant in
A549 tumours (Figure 5). We have obtained similar
results in PC3 prostate cancer xenografts (see Additional
file 1: Figure S1) indicating that these are likely universal
responses of human epithelial tumours to IR that are in-
dependent of K-Ras mutation status and LKB1 or p53
function. One could contribute the suppressed mTOR
activity in xenografts on the enhanced AMPK activity.
However, the mechanism of reduced phosphorylation
of Akt remains unclear and needs to be elucidated by
future studies. Nevertheless, the concept of Akt inhib-
ition in tumours by agents that activate the AMPK path-
way has been described in earlier studies by our group
and others [22,23]. It is possible that in irradiated
tumours conditions develop, long after delivery of IR,
that attenuate signal transduction between ATM and
Akt leading to suppression of Akt and mTOR activity
despite enhanced ATM activation. In irradiated tumours
the combined effects of sustained increased expression
of AMPK-p53-p21cip1/p27kip1 pathway, that is shown to
lead to inhibition of cell cycling, and inhibition of Akt-
mTOR-4EBP1 pathway, known to lead to gene tran-
scription and translation, may be capable of mediating
an effective anti-proliferative action in those tumours,
which may be adequate to mediate the cytotoxic action
of IR [13]. Future studies should examine causality in
the relationship between these events.
Our observation of sustained ATM activity in irra-
diated tumours is a significant finding of the present
study. Since ATM is suggested to be a common regula-
tor of the activity of the AMPK-p53/p21cip1/p27kip1 and
Akt-mTOR-4EBP1 pathways [6,14], future work should
address the mechanism of this sustained activation of
ATM in irradiated tissues. It is possible that ATM acti-
vation is the result of sustained, IR-induced DNA dam-
age or genomic instability that remains in tumours
long after irradiation. Other mechanisms of ATM acti-
vation have been described, including hypoxia. Since IR
is known to damage tumour vascular supply one could
hypothesize that the sustained ATM activity of irra-
diated tumours may be the result of hypoxia develop-
ing in these tissues rather than sustained DNA
damage. Conceivably, the reduced vascular supply and
CD31 expression we observed in irradiated xenografts
here would be responsible for local tumour hypoxia
and the enhanced expression of HIF1α we observed
(Figure 6). Interestingly, Cam et al. [24] showed that in
hypoxic conditions ATM mediates phosphorylation of
HIF1α leading to activation of this molecule and inhib-
ition of mTORC1.
Conclusions
This study explored in tumours the long-term regulation
by IR of two key tumour suppression or growth pathways
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lished acute activation of both the AMPK and Akt-
mTOR pathways by IR, irradiated tumours showed a sus-
tained expression and activation of the AMPK-p53/
p21cip1/p27kip1 but inhibition of the activity of the Akt-
mTOR-4EBP1 pathway. This was associated with increased
expression and sustained activity of the upstream regula-
tor of the two pathways ATM that may be associated
with the development of hypoxia in irradiated tumours
or with potential genomic instability. These molecular
responses of irradiated tumours do not appear to be
dependent on typical oncogenic molecular defects detected
in lung cancer involving K-Ras, LKB1 or p53 status. The
findings of this study provide a basis to understand better
the chronic regulation of these key pathways by IR alone.
IR causes a favorable but partial modification of the activ-
ity of the studied pathways. Additional modulation of
those pathways with targeted therapies may be able to
improve further radiotherapy responses in lung cancer.
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Additional file 1: Figure S1. The effects of ionizing radiation on PC3
prostate cancer xenografts. PC3 cells were grafted into the flanks of balb/c
nude mice and were treated with or without a single fraction of 10Gy IR.
The average tumour volumes from each group were measured and
expressed as the mean±SE of 6 animals per group. A. Extracted PC3
tumours were lysed and subjected to western blotting with antibodies
against the AMPK pathway. B. Normalized densitometry values of the
results from A. (mean ±SE) of 6 animals per groups are shown. C.
Extracted PC3 tumours were lysed and subjected to immunoblotting
with antibodies against the Akt-mTOR pathway. D. Normalized
densitometry values of the results from C. (mean ±SE) of 6 animals per
groups are shown.
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